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Abstract 
Objectives:  To examine predictors of enucleation and morcellation time within a large cohort of 
men undergoing HoLEP for benign prostatic hypertrophy. 
Methods:  Pre-operative, peri-operative, and post-operative clinical characteristics were 
available from men treated with HoLEP between 1998 and 2013 at Indiana University Health 
Methodist Hospital.  Stepwise linear regression was performed to determine clinical variables 
which are associated with enucleation and morcellation times.  
Results:  We identified 960 patients who underwent HoLEP.  Average (range) enucleation time 
was 65.7 (11-245) minutes and morcellation time was 19.7 (3-260) minutes.  History of 
anticoagulation was associated with a small decrease in enucleation time (p=0.013) while 
increasing HoLEP specimen weight was associated with increasing enucleation time (p<0.001).  
History of intermittent catheterization, urinary tract infections, presence of dense prostatic tissue 
(colloquially referred to as “beach balls”), and increasing specimen weight were associated with 
increasing morcellation time (p<0.05 each).  Having HoLEP performed by a less experienced 
urologist was associated with longer enucleation and morcellation times. 
Conclusions:  Prostate volume is significantly associated with increased enucleation and 
morcellation times during HoLEP.  Additionally, history of UTI and CIC are associated with 
modest increases in enucleation and morcellation times.  Dense enucleated prostate tissue 
significantly impacts the ability to morcellate effectively.  Increasing surgeon experience can 
significantly improve both enucleation and morcellation efficiency. 
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Introduction 
Since its introduction in the late 1990s1, holmium laser enucleation of the prostate 
(HoLEP) has increased in popularity for management of benign prostatic hyperplasia (BPH).  
Evidence suggests that HoLEP provides superior outcomes compared to TURP and open simple 
prostatectomy in men with BPH, regardless of prostate size2-5.  Additionally, a recent study 
found that HoLEP is associated with decreased hospital costs compared to open prostatectomy.6  
Performance and efficiency of HoLEP relies on two critical steps—transitional zone 
enucleation followed by tissue morcellation.  Enucleation and morcellation times are dependent 
upon a number of factors including prostatic volume, as well as tissue quality.  Because a steep 
learning curve and the potential for long operative times with HoLEP are common criticisms of 
the procedure, we sought to evaluate pre-HoLEP variables that may impact both enucleation and 
morcellation times during surgery.   
 
Materials and methods 
Patients, outcomes, and variables 
 After obtaining Institutional Review Board (IRB) approval (Protocol #1010002242), we 
conducted a retrospective cohort analysis using the prospectively collected IU Health Methodist 
Hospital database to identify patients who underwent HoLEP between 1998 and 2013.  The 
primary outcomes of interest were enucleation and morcellation times.  Variables included in the 
analysis were age, pre-HoLEP PSA, history of 5-alpha reductase inhibitor (5ARI) or alpha 
blocker therapy, history of urinary retention, history of recurrent urinary tract infections (UTI), 
history of anticoagulation, transrectal ultrasound (TRUS) prostate volume, final pathological 
HoLEP specimen weight (<30g, 30-100g, 100-150g, and >150g), presence of prostatic 
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malignancy in HoLEP specimen, and surgeon experience (experienced vs. less experienced).  
The majority of surgeries were performed by a single experienced surgeon (JEL) who has 
performed over 2,000 HoLEP operations at IU Health Methodist Hospital.  The remaining 
HoLEP cases were performed by six surgeons, all with less than 100 procedures on record at our 
hospital.  Patients who did not have a recorded pre-HoLEP PSA, pertinent medical history details 
(variables included in the regression), pathologic details, and enucleation or morcellation times 
were excluded (n=560). There were no statistical differences in pre-operative PSA (when 
available) between the patients included in and excluded from the study. 
 
Description of procedure 
 Using a 100 W Ho:YAG laser source, configured with a 550-nm end-fire laser fiber, the 
HoLEP procedure was performed as previously described7.  A 28 F continuous-flow 
resectoscope (Karl Storz Endoscopy, Culver City, CA, USA) with a laser bridge housing a 7 F 
stabilizing catheter (Cook Urologic, Spencer, IN, USA) was used to enucleate the prostate.  
Normal saline was used as the irrigant in all cases.  Briefly, the enucleation requires laser settings 
of 2 J and 40-50 Hz for the lateral lobes, 2 J and 20 Hz for the apical dissection, and 2 J and 20 
Hz to divide the apical mucosal bridges. 
 
 Tissue morcellation was achieved using a Lumenis VersaCut™ tissue morcellator 
(Lumenis Ltd, Yokneam, Israel) introduced through a Storz nephroscope.  Dual irrigation is used 
to keep the bladder full and to improve visualization.  Irrigation was placed approximately 24-30 
inches above the level of the bladder.  Unusually tough prostatic tissue (termed “beach balls”) 
may occasionally be encountered during enucleation which can prolong morcellation time.  
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Often these “beach balls” can be refractory to traditional morcellation techniques.  When 
encountered, management options include removing pieces with grasping forceps, exchanging 
morcellation blades, and lasering into smaller pieces to facilitate engagement into the 
morcellator.  As a last resort, a small cystotomy can be performed to remove residual tissue.   
 
Statistical analyses 
 In order to identify potential predictors of enucleation time and morcellation time, 
separate forward and backward stepwise linear regression models were performed using p<0.2 as 
our criteria for model inclusion.  All variables included in the descriptive analysis were included 
in the initial stepwise linear regression models and only variables that were identified as 
significant (p<0.2) were included in the final presented multiple linear regression models.  A 
priori p<0.05 was set as the threshold for statistical significance for the final multiple linear 
regression models.  All statistical analyses were performed using Stata version 13.0 (Statacorp, 
College Station, TX).  
 
Results 
 Clinical pre-operative, peri-operative, and post-operative characteristics of our patient 
cohort are shown in Table 1.  There were a total of 960 patients with an average age of 70 years.  
The majority of patients had a history of either 5ARI and/or alpha blocker therapy (79%).  
Twenty-six percent had urinary retention at the time of HoLEP (Table 1).  Nearly 90% of 
HoLEPs were performed by a single surgeon.  Mean enucleation time was 66 minutes while 
mean morcellation time was 20 minutes.  Enucleation rates varied significantly between 
experienced and less experienced surgeons with enucleation rates of 1.46g/min (0.9) for 
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experienced and 0.77g/min (0.6) for less experienced surgeons (p<0.001).  Similar findings were 
observed for morcellation rate with 5.45g/min for experienced and 4.21g/min for less 
experienced surgeons (p<0.001).  Of note, among cases where prostate “beach balls” were 
mentioned in the operative report (n=34, 3.5%), the average morcellation time was 51.4 minutes 
compared with 18.5 minutes in non-“beach ball” patients (p<0.001).   
 
Enucleation time 
 Variables identified from the stepwise linear regression models as being associated with 
enucleation time included urinary retention, history of UTI, history of anticoagulation, HoLEP 
specimen weight, presence of  “beach balls” in operative report, and surgeon experience (Table 
2).  In the final model, history of anticoagulation was associated with a five minute decrease in 
enucleation time (p=0.024).  Less experienced surgeons had an estimated 21 minute increase in 
enucleation time (p<0.001).  Compared with specimen weight of <30g, each progressive 
specimen weight category was associated with significant increases in enucleation time ranging 
from 18 to 40 minutes (Table 2).   
 
Morcellation time 
 Variables identified from the stepwise linear regression models as being associated with 
morcellation time included history of 5ARI therapy, history of UTI, HoLEP specimen weight, 
presence of ”beach balls”, and experience of the surgeon (Table 3).  In the final multiple linear 
regression model, history of UTI was associated with a significant increase in morcellation time 
by 2.5 minutes.  Adjusting for the other covariates in the model, presence of “beach balls” 
7 
 
conferred a 25 minute increase in morcellation time.  Additionally, increasing HoLEP specimen 
weight conferred a 9-40 minute increase in morcellation time (Table 3).  
 
Discussion 
 Considerable level one evidence has demonstrated the benefits of HoLEP over simple 
prostatectomy and TURP for the treatment of BPH in large glands8-14.  Amongst established 
benefits of HoLEP are its long term, durable, and reproducible results that can be applied to any 
prostate gland size12,15,16.  A frequently reported criticism of HoLEP is the length of the 
procedure, as well as the steep learning curve associated with surgical efficiency.  Thus, 
understanding patient and tissue variables that may impact operative time may assist in patient 
counseling, scheduling of efficient OR time, and proper patient selection for surgeons in various 
stages of experience. 
 Enucleation involves complete removal of the transitional zone of the prostate using a 
holmium-YAG laser.  This is not a vaporization procedure but rather the laser is used as a cutting 
tool.  Enucleation time largely depends upon prostate size, configuration, and visualization.  
Similarly, morcellation time is impacted both by enucleation volume and visualization.  As such, 
it is not surprising that HoLEP specimen weight was associated with significant increases in 
enucleation and morcellation time.  Multiple previous studies have suggested this relationship 
with many further reporting that HoLEP operative efficiency increases with larger prostate 
volumes17-20.  Interestingly, and in line with our findings, studies have suggested that as surgeons 
become more comfortable with performing HoLEP, the enucleation and morcellation time 
decreases19.  Not unexpectedly, patients with “beach ball” enucleated tissue encountered during 
HoLEP had significantly longer morcellation times.  Identifying factors contributing to the 
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formation of these dense tissue pieces is worth investigation in future studies.  Recently, the 
introduction of new morcellators (Wolf Piranha, Knittlingen, Germany) has greatly reduced this 
problem. 
 Elzayat et al examined the safety of HoLEP in chronically anticoagulated patients and 
found that HoLEP was a safe option for this patient population21.  This is not surprising as the 
holmium-YAG laser effectively coagulates while enucleating the tissue8.  We initially 
hypothesized that chronic anti-coagulation may worsen enucleation and/or morcellation times as 
this could negatively impact visualization during surgery.21  Interestingly, our study found that a 
history of chronic anticoagulation was associated with a small but significant decrease in 
enucleation time.  Although we are unable to explain this relationship, we speculate, because of 
anticipated concern regarding intra-operative bleeding, that this may actually reflect earlier 
participation by senior staff and thus decreased resident or fellow participation in the enucleation 
portion of the case. 
 The learning curve associated with HoLEP is often considered a disadvantage to the 
procedure despite studies suggesting that proficiency can be gained in as little as two dozen 
procedures22,23.  Furthermore, studies have reported that there is little variation in operative 
efficiency between surgeons and that comparable times can be achieved17,24.  We found that 
although there is a twenty minute increase in enucleation time associated with less experienced 
surgeons, there is minimal difference in morcellation time.  Enucleation is the more time-
consuming portion of HoLEP and we believe that efficiency likely improves with surgeon 
experience.  Of note, the impact of tissue quality, i.e. prostatic “beach balls”, is an important 
determinant of time regardless of surgeon experience, although surgeon experience certainly 
diminishes the impact that difficult tissue has on overall operative times. 
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 We examined whether recurrent UTI, chronic anticoagulation, and urinary retention 
(catheter or CIC leading up to surgery) would impact morcellation or enucleation time.  We 
hypothesized that each of these might play a significant role because of their potential to impact 
prostatic tissue quality.  Recent studies have evaluated the relationship between chronic prostatic 
inflammation with urinary retention and BPH progression with the finding that patients with 
chronic prostate inflammation have significantly higher risk of retention25.  Recurrent UTI and 
chronic urinary catheterization can all hypothetically increase prostate inflammation, although 
studies examining this relationship have failed to demonstrate consistent findings25,26.  Prostate 
inflammation impacts the histologic architecture, increasing gland volume and obliterates the 
natural plane between adenoma and prostate capsule which may result in a more complicated 
dissection during enucleation.  Inflamed prostate tissue may also trigger increased bleeding or 
oozing while operating which may result in poorer visualization requiring increased time to 
achieve appropriate hemostasis during surgery.  Furthermore, changes in gland volume and 
tissue quality may hinder morcellation as well, increasing surgical times in this select group of 
patients25,26.  In our study, requiring a Foley at the time of HoLEP was not associated with 
increases in either enucleation or morcellation time.  History of UTI, however, was associated 
with a modest increase in both surgical steps.   
 The impact of 5ARIs on prostatic tissue quality is not well understood but 5ARIs are 
known to affect the glandular to stromal ratio with an overall reduction in glandular tissue27-28. 
Therefore, hypothetically, long-term use of 5ARIs might increase the fibrous content of the 
prostate which could make enucleation and morcellation more difficult.  We were surprised to 
find, therefore, that the use of 5ARI did not appear to affect our operative times.  Sandfeldt et al 
reported a reduction in blood loss during transurethral resection of the prostate after 3 months of 
10 
 
preoperative treatment with finasteride. However, in our experience, 5ARI use was not 
associated with any bleeding reduction during HoLEP29. Warner et al previously examined the 
impact of 5ARIs on HoLEP and reported that history of use does not impact HoLEP outcomes or 
operative time which is consistent with our findings30.  Interestingly, in the current study we 
report that history of 5ARI was actually associated with a faster enucleation rate, although it did 
not reach statistical significance.  Additionally, we observed shorter morcellation times in these 
patients.  Whether these findings are related to random occurrence, reduced prostate volume 
associated with 5ARI use, or more senior participation during surgery remains unknown.  In any 
event, there does not appear to be a clear relationship between 5ARI use and overall operative 
times during HoLEP.  
 This study is not devoid of limitations.  It is retrospective in nature, although the data are 
collected in a prospective fashion.  Additionally, complete preoperative data was not available 
for all patients and may have impacted results.  As this study spans over a 15 year period, 
differences in patients and techniques may exist.  Despite these limitations, this study is the first 
to examine how preoperative variables may impact enucleation and morcellation times in 
patients undergoing HoLEP for BPH. 
 
Conclusions 
 HoLEP is an effective therapy for the management of BPH symptoms, particularly in 
men with large prostate glands.  The duration of HoLEP is dependent upon prostate size, tissue 
quality, and surgeon’s experience.  A history of UTI is associated with an increase in operative 
time while anticoagulation is associated with a decrease in operative time.  As surgeons gain 
proficiency and experience in performing HoLEP, enucleation and morcellation times decrease.  
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Table 1.  Characteristics of patients undergoing HoLEP  
 Patients (n%) 
Total patients 960 
Age (years), mean (SD) 70.4 (8) 
History of 5ARI use 323 (33.7) 
History of alpha blocker use 696 (72.5) 
Requiring Foley at time of HoLEP 250 (26.0) 
History of UTI 393 (40.9) 
History of anticoagulation 201 (20.9) 
Pre-HoLEP PSA (ng/ml), mean (range) 8.1 (0.04-449.4) 
TRUS weight (g), mean (SD) a 102.8 (51) 
PSA density, mean (SD) b 0.10 (0.38) 
Beach ball identified 34 (3.5) 
Enucleation time (min), average (range) 65.7 (11-245) 
Morcellation time (min), average (range) 19.7 (3-260) 
HoLEP specimen weight (g)  
    <30g 147 (15.3) 
    30-100g 499 (52.0) 
    100-150g 218 (22.7) 
    >150g 96 (10.0) 
Enucleation rate (g/min), average (SD) 1.38 (0.9) 
Morcellation rate (g/min), average (SD) 5.32 (2.8) 
Presence of prostate cancer 84 (8.8) 
Less experienced surgeon 107 (11.2) 
a TRUS weight unavailable for 103/960 
b PSA density unavailable for 125/960 
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Table 2.  Predictors of enucleation time from multiple linear regression model 
Characteristic Coefficient 
(minutes) 
95% CI p-value 
Requiring Foley at time of HoLEP -3.49 -7.98-1.00 0.127 
History of UTI 2.83 -0.71-6.38 0.117 
History of anticoagulation -4.93 -9.22- -0.64 0.024 
HoLEP specimen weight    
    <30g Reference   
    30-100g 17.86 12.85-22.87 <0.001 
    100-150g 31.55 25.76-37.33 <0.001 
    >150g 39.81 32.69-46.93 <0.001 
Less experienced surgeon 20.86 15.28-26.44 <0.001 
Beach ball present -7.94 -17.38-1.50 0.099 
Constant 43.76 39.00-48.52 <0.001 
Interpretation of linear regression model: for a patient not requiring a Foley at time of HoLEP but with a 
history of UTI and anticoagulation, who had a HoLEP specimen weight of 125g, with HoLEP performed 
by an experienced surgeon, and no beach balls, the estimated enucleation time is 73.2 minutes (0+2.83-
4.93+0+31.55+0+0+43.76=73.2).  Negative coefficients represent decreases in estimated morcellation 
time.  
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Table 3.  Predictors of morcellation time from multiple linear regression model 
Characteristic Coefficient 
(minutes) 
95% CI p-value 
History of 5ARI -1.28 -3.32-0.77 0.220 
History of UTI 2.45 0.50-4.40 0.014 
HoLEP specimen weight    
    <30g Reference   
    30-100g 8.84 6.07-11.60 <0.001 
    100-150g 21.59 18.39-24.78 <0.001 
    >150g 39.71 35.77-43.65 <0.001 
Less experienced surgeon 3.00 -0.08-6.08 0.056 
Beach ball present 25.26 20.10-30.42 <0.001 
Constant 4.47 1.83-7.10 0.001 
Interpretation of linear regression model: for a patient with a history of 5ARI use, no history of UTI, 
HoLEP specimen weight of 125g, with HoLEP performed by a less experienced surgeon, and no beach 
balls present, the estimated morcellation time is 24.8 minutes (-1.28+0+21.59+ 3.0+0+4.47=24.8).  
Negative coefficients represent decreases in estimated enucleation time.  
 
 
